Acute ‘strokenomics’: efficacy and economic analyses of alteplase for acute ischemic stroke

References

• Seshadri S, Beiser A, Kelly-Hayes M et al. The lifetime risk of stroke: estimates from the Framingham Study. Stroke37(2), 345–350 (2006).
   PubMed Web of Science ®Google Scholar
• Rich DQ, Gaziano JM, Kurth T. Geographic patterns in overall and specific cardiovascular disease incidence in apparently healthy men in the United States. Stroke38(8), 2221–2227 (2007).
   Google Scholar
• Hallstrom B, Jonsson AC, Nerbrand C, Norrving B, Lindgren A. Stroke incidence and survival in the beginning of the 21st Century in southern Sweden: comparisons with the late 20th Century and projections into the future. Stroke39(1), 10–15 (2008).
   PubMed Web of Science ®Google Scholar
• Durai PJ, Padma V, Vijaya P, Sylaja PN, Murthy JM. Stroke and thrombolysis in developing countries. Int. J. Stroke2(1), 17–26 (2007).
   Google Scholar
• Dawson J, Lees JS, Chang TP et al. Association between disability measures and healthcare costs after initial treatment for acute stroke. Stroke38(6), 1893–1898 (2007).
   PubMed Web of Science ®Google Scholar
• Schmulling S, Grond M, Rudolf J, Heiss WD. One-year follow-up in acute stroke patients treated with rtPA in clinical routine. Stroke31(7), 1552–1554 (2000).
   PubMed Web of Science ®Google Scholar
• Dhamoon MS, Moon YP, Paik MC et al. Long-term functional recovery after first ischemic stroke: the Northern Manhattan Study. Stroke40(8), 2805–2811 (2009).
   PubMed Web of Science ®Google Scholar
• Qureshi AI, Suri MF, Nasar A et al. Changes in cost and outcome among US patients with stroke hospitalized in 1990 to 1991 and those hospitalized in 2000 to 2001. Stroke38(7), 2180–2184 (2007).
   Google Scholar
• Luengo-Fernandez R, Gray AM, Rothwell PM. Population-based study of determinants of initial secondary care costs of acute stroke in the United Kingdom. Stroke37(10), 2579–2587 (2006).
   PubMedGoogle Scholar
• Luengo-Fernandez R, Gray AM, Rothwell PM. Costs of stroke using patient-level data: a critical review of the literature. Stroke40(2), e18–e23 (2009).
   PubMed Web of Science ®Google Scholar
• Demaerschalk BM, Yip TR. Economic benefit of increasing utilization of intravenous tissue plasminogen activator for acute ischemic stroke in the United States. Stroke36(11), 2500–2503 (2005).
   PubMed Web of Science ®Google Scholar
• Grieve R, Hutton J, Bhalla A et al. A comparison of the costs and survival of hospital-admitted stroke patients across Europe. Stroke32(7), 1684–1691 (2001).
   PubMed Web of Science ®Google Scholar
• Naess H, Waje-Andreassen U, Thomassen L, Nyland H, Myhr KM. Health-related quality of life among young adults with ischemic stroke on long-term follow-up. Stroke37(5), 1232–1236 (2006).
   PubMed Web of Science ®Google Scholar
• Earnshaw SR, Jackson D, Farkouh R, Schwamm L. Cost–effectiveness of patient selection using penumbral-based MRI for intravenous thrombolysis. Stroke40(5), 1710–1720 (2009).
   PubMed Web of Science ®Google Scholar
• Saver JL. Time is brain – quantified. Stroke37(1), 263–266 (2006).
   PubMed Web of Science ®Google Scholar
• Lees KR. ECASS-II: intravenous alteplase in acute ischaemic stroke. European Co-operative Acute Stroke Study-II. Lancet353(9146), 65–66 (1999).
   Google Scholar
• Fagan SC, Morgenstern LB, Petitta A et al. Cost–effectiveness of tissue plasminogen activator for acute ischemic stroke. NINDS rt-PA Stroke Study Group. Neurology50(4), 883–890 (1998).
   PubMed Web of Science ®Google Scholar
• Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA282(21), 2019–2026 (1999).
   PubMed Web of Science ®Google Scholar
• Quinn TJ, Dawson J, Lees KR. Past, present and future of alteplase for acute ischemic stroke. Expert Rev. Neurotherapeutics8, 181–192 (2008).
   PubMedGoogle Scholar
• Hacke W, Donnan G, Fieschi C et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet363(9411), 768–774 (2004).
   PubMed Web of Science ®Google Scholar
• Hacke W, Kaste M, Bluhmki E et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N. Engl. J. Med.359(13), 1317–1329 (2008).
   PubMed Web of Science ®Google Scholar
• Saver JL. Number needed to treat estimates incorporating effects over the entire range of clinical outcomes: novel derivation method and application to thrombolytic therapy for acute stroke. Arch. Neurol.61(7), 1066–1070 (2004).
   PubMed Web of Science ®Google Scholar
• Saver JL. Hemorrhage after thrombolytic therapy for stroke: the clinically relevant number needed to harm. Stroke38(8), 2279–2283 (2007).
   PubMed Web of Science ®Google Scholar
• IST Investigators. The International Stroke Trial (IST), a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. Lancet349(9065), 1569–1581 (1997).
   PubMed Web of Science ®Google Scholar
• Langhorne P, Williams BO, Gilchrist W, Dennis MS, Slattery J. A formal overview of stroke unit trials. Rev. Neurol.23(120), 394–398 (1995).
   PubMedGoogle Scholar
• Langhorne P. The role of stroke units. Ir. Med. J.88(5), 150 (1995).
   Google Scholar
• Gilligan AK, Thrift AG, Sturm JW, Dewey HM, Macdonell RA, Donnan GA. Stroke units, tissue plasminogen activator, aspirin and neuroprotection: which stroke intervention could provide the greatest community benefit? Cerebrovasc. Dis.20(4), 239–244 (2005).
   PubMedGoogle Scholar
• Moodie ML, Carter R, Mihalopoulos C et al. Trial application of a Model of Resource Utilization, Costs, and Outcomes for Stroke (MORUCOS) to assist priority setting in stroke. Stroke35(5), 1041–1046 (2004).
   PubMed Web of Science ®Google Scholar
• Wahlgren N, Ahmed N, Davalos A et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST), an observational study. Lancet369(9558), 275–282 (2007).
   PubMed Web of Science ®Google Scholar
• Albers GW, Bates VE, Clark WM, Bell R, Verro P, Hamilton SA. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA283(9), 1145–1150 (2000).
   PubMed Web of Science ®Google Scholar
• Sylaja PN, Cote R, Buchan AM, Hill MD. Thrombolysis in patients older than 80 years with acute ischaemic stroke: Canadian Alteplase for Stroke Effectiveness Study. J. Neurol. Neurosurg. Psychiatry77(7), 826–829 (2006).
   PubMed Web of Science ®Google Scholar
• Adams HP Jr, del Zoppo G, Alberts MJ et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke38(5), 1655–1711 (2007).
   PubMed Web of Science ®Google Scholar
• Chung H, Refoios CR, Barnett D. Alteplase for the treatment of acute ischaemic stroke: NICE technology appraisal guidance. Heart93(12), 1616–1617 (2007).
   Google Scholar
• Alvarez-Sabin J, Molina CA, Montaner J et al. Effects of admission hyperglycemia on stroke outcome in reperfused tissue plasminogen activator--treated patients. Stroke34(5), 1235–1241 (2003).
   PubMed Web of Science ®Google Scholar
• Yong M, Kaste M. Association of characteristics of blood pressure profiles and stroke outcomes in the ECASS-II trial. Stroke39(2), 366–372 (2008).
   PubMed Web of Science ®Google Scholar
• Sare GM, Ali M, Shuaib A, Bath PM. Relationship between hyperacute blood pressure and outcome after ischemic stroke: data from the VISTA collaboration. Stroke40(6), 2098–2103 (2009).
   PubMed Web of Science ®Google Scholar
• Rudd AG, Hoffman A, Irwin P, Lowe D, Pearson MG. Stroke unit care and outcome: results from the 2001 National Sentinel Audit of Stroke (England, Wales, and Northern Ireland). Stroke36(1), 103–106 (2005).
   Google Scholar
• Horowitz SH. Thrombolytic therapy in acute stroke: neurologists, get off your hands! Arch. Neurol.55(2), 155–157 (1998).
   Google Scholar
• Innes K. Thrombolysis for acute ischaemic stroke: core nursing requirements. Br. J. Nurs.12(7), 416–424 (2003).
   Google Scholar
• Wardlaw JM, Seymour J, Cairns J, Keir S, Lewis S, Sandercock P. Immediate computed tomography scanning of acute stroke is cost-effective and improves quality of life. Stroke35(11), 2477–2483 (2004).
   PubMed Web of Science ®Google Scholar
• Bornstein NM. Dedicated stroke units and outcome. Isr. Med. Assoc.J.7(11), 739 (2005).
   Google Scholar
• Kwan J, Hand P, Sandercock P. Improving the efficiency of delivery of thrombolysis for acute stroke: a systematic review. QJM97(5), 273–279 (2004).
   PubMed Web of Science ®Google Scholar
• Kwan J, Hand P, Sandercock P. A systematic review of barriers to delivery of thrombolysis for acute stroke. Age Ageing33(2), 116–121 (2004).
   PubMed Web of Science ®Google Scholar
• Juttler E, Schwab S, Schmiedek P et al. Decompressive Surgery for the Treatment of Malignant Infarction of the Middle Cerebral Artery (DESTINY), a randomized, controlled trial. Stroke38(9), 2518–2525 (2007).
   PubMed Web of Science ®Google Scholar
• Sandercock P, Berge E, Dennis M et al. Cost–effectiveness of thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke assessed by a model based on UK NHS costs. Stroke35(6), 1490–1497 (2004).
   PubMed Web of Science ®Google Scholar
• Sinclair SE, Frighetto L, Loewen PS et al. Cost-Utility analysis of tissue plasminogen activator therapy for acute ischaemic stroke: a Canadian healthcare perspective. Pharmacoeconomics19(9), 927–936 (2001).
   PubMed Web of Science ®Google Scholar
• Chambers M, Koch P, Hutton J. Development of a decision analytical model of stroke care in United States and Europe. Value Health5, 85–97 (2002).
   Google Scholar
• Samsa GP, Reutter RA, Parmigiani G et al. Performing cost–effectiveness analysis by integrating randomized trial data with a comprehensive decision model: application to treatment of acute ischemic stroke. J. Clin. Epidemiol.52(3), 259–271 (1999).
   PubMed Web of Science ®Google Scholar
• Yip TR, Demaerschalk BM. Estimated cost savings of increased use of intravenous tissue plasminogen activator for acute ischemic stroke in Canada. Stroke38(6), 1952–1955 (2007).
   PubMed Web of Science ®Google Scholar
• Ehlers L, Muskens WM, Jensen LG, Kjolby M, Andersen G. National use of thrombolysis with alteplase for acute ischaemic stroke via telemedicine in Denmark: a model of budgetary impact and cost effectiveness. CNS Drugs22(1), 73–81 (2008).
   PubMed Web of Science ®Google Scholar
• Ehlers L, Andersen G, Clausen LB, Bech M, Kjolby M. Cost–effectiveness of intravenous thrombolysis with alteplase within a 3-hour window after acute ischemic stroke. Stroke38(1), 85–89 (2007).
   PubMed Web of Science ®Google Scholar
• Mar J, Begiristain JM, Arrazola A. Cost–effectiveness analysis of thrombolytic treatment for stroke. Cerebrovasc. Dis.20(3), 193–200 (2005).
   PubMedGoogle Scholar
• Nadareishvili Z, Oh P, Smurawska LT, Tran C, Norris JW. Cost–effectiveness of tissue plasminogen activator for acute ischemic stroke. Neurology52(4), 895–896 (1999).
   Google Scholar
• Scott PA, Silbergleit R. Economic benefit of increasing utilization of intravenous tissue plasminogen activator for acute ischemic stroke in the United States. Stroke37(4), 943–944 (2006).
   Google Scholar
• Barradell LB, Goa KL. Alteplase: a pharmacoeconomic evaluation of its use in the management of myocardial infarction. Pharmacoeconomics8(5), 428–459 (1995).
   Google Scholar
• Wardlaw JM, del Zoppo G, Yamaguchi T, Berge E. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst. Rev.4, CD000213 (2009).
   PubMedGoogle Scholar
• Grieve R, Hutton J, Bhalla A et al. A comparison of the costs and survival of hospital-admitted stroke patients across Europe. Stroke32(7), 1684–1691 (2001).
   PubMed Web of Science ®Google Scholar
• Nadeau JO, Shi S, Fang J et al. TPA use for stroke in the Registry of the Canadian Stroke Network. Can. J. Neurol. Sci.32(4), 433–439 (2005).
   PubMed Web of Science ®Google Scholar
• Kulkens S, Hacke W. Thrombolysis with alteplase for acute ischemic stroke: review of SITS-MOST and other Phase IV studies. Expert Rev. Neurother.7(7), 783–788 (2007).
   PubMedGoogle Scholar
• Ingall TJ, O’Fallon WM, Asplund K et al. Findings from the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial. Stroke35(10), 2418–2424 (2004).
   PubMed Web of Science ®Google Scholar
• Demaerschalk BM, Bobrow BJ, Paulsen M. Development of a metropolitan matrix of primary stroke centers: the Phoenix experience. Stroke39(4), 1246–1253 (2008).
   PubMed Web of Science ®Google Scholar
• Hacke W, Albers G, Al Rawi Y et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS), a Phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke36(1), 66–73 (2005).
   PubMed Web of Science ®Google Scholar
• Edwards LL. Using tPA for acute stroke in a rural setting. Neurology68(4), 292–294 (2007).
   Google Scholar
• Scott PA, Temovsky CJ, Lawrence K, Gudaitis E, Lowell MJ. Analysis of Canadian population with potential geographic access to intravenous thrombolysis for acute ischemic stroke. Stroke29(11), 2304–2310 (1998).
   PubMed Web of Science ®Google Scholar
• Uren B, Lowell MJ, Silbergleit R. Critical care transport of patients who have acute neurological emergencies. Emerg. Med. Clin. North Am.27(1), 17–26, VII (2009).
   Google Scholar
• Audebert HJ, Kukla C, Clarmann VC et al. Telemedicine for safe and extended use of thrombolysis in stroke: the Telemedic Pilot Project for Integrative Stroke Care (TEMPiS) in Bavaria. Stroke36(2), 287–291 (2005).
   PubMed Web of Science ®Google Scholar
• Silliman SL, Quinn B, Huggett V, Merino JG. Use of a field-to-stroke center helicopter transport program to extend thrombolytic therapy to rural residents. Stroke34(3), 729–733 (2003).
   PubMed Web of Science ®Google Scholar
• Silbergleit R, Scott PA, Lowell MJ, Silbergleit R. Cost–effectiveness of helicopter transport of stroke patients for thrombolysis. Acad. Emerg. Med.10(9), 966–972 (2003).
   PubMed Web of Science ®Google Scholar
• Meseguer E, Labreuche J, Olivot JM et al. Determinants of outcome and safety of intravenous rt-PA therapy in the very old: a clinical registry study and systematic review. Age Ageing37(1), 107–111 (2008).
   Google Scholar
• Mateen FJ, Nasser M, Spencer BR et al. Outcomes of intravenous tissue plasminogen activator for acute ischemic stroke in patients aged 90 years or older. Mayo Clin. Proc.84(4), 334–338 (2009).
   PubMed Web of Science ®Google Scholar
• Boode B, Welzen V, Franke C, van Oostenbrugge R. Estimating the number of stroke patients eligible for thrombolytic treatment if delay could be avoided. Cerebrovasc. Dis.23(4), 294–298 (2007).
   Google Scholar
• Cocho D, Belvis R, Marti-Fabregas J et al. Reasons for exclusion from thrombolytic therapy following acute ischemic stroke. Neurology64(4), 719–720 (2005).
   PubMed Web of Science ®Google Scholar
• Walters MR, Muir KW, Harbison J, Lees KR, Ford GA. Intravenous thrombolysis for acute ischaemic stroke: preliminary experience with recombinant tissue plasminogen activator in the UK. Cerebrovasc. Dis.20(6), 438–442 (2005).
   PubMed Web of Science ®Google Scholar
• Quinn TJ, Cameron AC, Dawson J, Lees KR, Walters MR. ABCD2 scores and prediction of noncerebrovascular diagnoses in an outpatient population: a case-control study. Stroke40(3), 749–753 (2009).
   PubMed Web of Science ®Google Scholar
• Nguyen-Huynh MN, Johnston SC. Is hospitalization after TIA cost-effective on the basis of treatment with tPA? Neurology65(11), 1799–1801 (2005).
   PubMedGoogle Scholar